[{"id":"48b8d938-7f8b-4bf9-a8a6-3d05476c8d31","acronym":"","url":"https://clinicaltrials.gov/study/NCT03758287","created_at":"2021-01-17T17:24:54.380Z","updated_at":"2024-07-02T16:36:08.487Z","phase":"Phase 1/2","brief_title":"Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative","source_id_and_acronym":"NCT03758287","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR T790M negative","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • ningetinib (CT053PTSA)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 07/17/2023","study_completion_date":" 07/17/2023","last_update_posted":"2022-06-22"}]